Global Human Microbiome Therapeutics Market to witness growth during the forecast period 2019-2026

Hyderabad, April 29, 2019 -- The "Human Microbiomes Therapeutics Market : Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2019-2026" report has been added to Datamintelligence.com's offering.
Human Microbiome Therapeutics Market Dynamics
⦁The global market for ablation catheters is primarily driven by the rise in prevalence of Metabolic Diseases, Dermatological Conditions and Other Disorders (Cardiovascular, CNS, Cancer) with the increase in the elderly popuLation.
⦁Metabolic disorders are inherited from ancestors or acquired during their lifetime. These include lactose intolerance, cystinosis, type 1 diabetes, maple syrup urine disease, Gaucher’s disease, Fabry disease, Hartnup disease, Hunter syndrome, and Hurler syndrome.
⦁Dermatology condition is majorly driven by the rising prevalence of skin cancer and other skin diseases. Further, growing aesthetic appeal in young population positively impacts the market growth of this sector.
⦁AOBiome, LLC, MatriSys Biosystem, and Intrexon are some of the players who invested in microbiome therapeutics for dermatological conditions. AOBiome is considered as a critical player in this sector as its drug is in trials for several diseases such as Acne Vulgaris; Atopic Dermatitis Eczema; Allergic Rhinitis; and Chronic Wounds.
Human Microbiome Therapeutics Market Segmentation
⦁By disease indication, the human microbiome therapeutics market is segmented into gastrointestinal disorders, metabolic disorder, women health, cancer, and others.
⦁The gastrointestinal disorders share the most established market due to its Increasing incidences of gastrointestinal disorders followed by infectious diseases.
⦁Although gastrointestinal disorders are significant impacts on the economic burden, many digestive diseases are still poorly understood, and treatment options are far from optimal, leaving many patients dissatisfied with their current treatment.
⦁For instance, recurrence of Clostridium Difficile Infection (CDI) is around 25% and the chances of further recurrence rise to 65%. Microbiome therapeutics checks the repetition and thus, possess massive opportunity in this sector.
Human Microbiome Therapeutics Market Geographical Share
⦁North America market accounted for the largest share in the human microbiome therapeutics market. It is attributed to the increasing pipeline products to treat gastrointestinal disorders, dermatological indication, etc.
⦁The first launch of human microbiome therapeutics in the United States, could for the gastrointestinal disorders (Clostridium Difficile Infection (CDI) specifically for the recurrent CDI) and the dermatological indication (for acne vulgaris).
⦁Another drug for the same indication is SER-109 of Series Therapeutics. Series appears to be the leading pharmaceutical firm in the field of microbiome therapies. Series estimates 85,000 to 110,000 recurrent CDI patients in the U.S. (with a midpoint of 97,500); presumably, the range is the number of new patients each year.
⦁It is expected to hit the market in 2021 after the launch of RBX-2660 in 2020, thus contribute to increasing the market size of gastrointestinal disorder (recurrent CDI).
Key Points covered in the report
⦁Human Microbiome Therapeutics Market - Methodology and Scope
⦁Human Microbiome Therapeutics Market - Trends
⦁Human Microbiome Therapeutics Market - Industry Analysis
⦁Geographical Analysis
⦁Competitive Landscape
⦁Company Profiles

For more information about this report and to request for a free sample, visit https://www.datamintelligence.com/research-report/human-microbiome-therapeutics
DataM Intelligence also offers Custom Research services providing focused, comprehensive and tailored research.

DataM Intelligence 4Market Research is a market intelligence platform which gives access to syndicated, customised reports to its clients at one place. As a firm with rich experience in research and consulting across multiple domains we are one stop solution that will cater to the needs of clients in key business areas.

1st floor, Phoenix Tech Tower, Plo no: 14/46, Habsidguda, IDA-Uppal, Hyderabad-500039, Telangana.

This release was published on openPR.